Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
23 June 2000Website:
http://www.criver.comNext earnings report:
14 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 22 Nov 2024 23:01:46 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
CRL Latest News
CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is greater than the decline in revenues from the DSA segment.
While the revenue and earnings per share (EPS) for Charles River (CRL) provide insight into its performance for the quarter ending September 2024, it could be helpful to look at how these important figures stack up against Wall Street predictions and last year's results.
Charles River Laboratories (CRL) reported quarterly earnings of $2.59 per share, which is higher than the Zacks Consensus Estimate of $2.43 per share. This is a decrease compared to earnings of $2.72 per share from the same period last year.
Charles River (CRL) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories has announced the date for their third-quarter 2024 earnings release and conference call.
Charles River and Lundbeck have made a deal to use Logica in order to help discover new neurological medications.
STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical firm using its unique HyNap™ technology to create better cancer treatments, has reported important advancements after a successful meeting with the U.S. Food and Drug Administration (FDA). The company intends to resubmit its New Drug Application (NDA) for Dasynoc in the fourth quarter of 2024, taking into account the feedback from the Complete Response Letter (CRL) received from the FDA in July 2024. If the FDA establishes a timeline.
Charles River is working together with CEBINA on the DanubeNeuro program to promote new ideas in the field of neurodegeneration.
New biological information has been published from the IRO® Cell Therapy Manufacturing Platform. This data provides insights into the platform's capabilities. It highlights advancements in cell therapy production.
Charles River has formed a new partnership with Insightec to enhance the development of therapies that use focused ultrasound in the field of neuroscience.
What type of business is Charles River Laboratories International?
Charles River Laboratories International, Inc. is an American corporation that provides preclinical and clinical laboratory services to pharmaceutical, medical, and other industries, as well as government and academic organizations worldwide. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts, USA. Charles River Laboratories, Inc. provides a platform for conducting research on new drugs and treatment methods at any stage of development: specially bred rodents, over 150 laboratory and specialized disease strains, human cell materials, etc. The company also conducts safety testing of drugs, industrial chemicals, agrochemicals, consumer products, veterinary medicines, and medical devices through outsourcing.
What sector is Charles River Laboratories International in?
Charles River Laboratories International is in the Healthcare sector
What industry is Charles River Laboratories International in?
Charles River Laboratories International is in the Diagnostics & Research industry
What country is Charles River Laboratories International from?
Charles River Laboratories International is headquartered in United States
When did Charles River Laboratories International go public?
Charles River Laboratories International initial public offering (IPO) was on 23 June 2000
What is Charles River Laboratories International website?
https://www.criver.com
Is Charles River Laboratories International in the S&P 500?
Yes, Charles River Laboratories International is included in the S&P 500 index
Is Charles River Laboratories International in the NASDAQ 100?
No, Charles River Laboratories International is not included in the NASDAQ 100 index
Is Charles River Laboratories International in the Dow Jones?
No, Charles River Laboratories International is not included in the Dow Jones index
When was Charles River Laboratories International the previous earnings report?
No data
When does Charles River Laboratories International earnings report?
The next expected earnings date for Charles River Laboratories International is 14 February 2025